Morphic's MORF-057 Shows Positive Results in UC Main Cohort Study.

Morphic Therapeutic has reported positive topline data from the main cohort of the open-label EMERALD-1 Phase 2a study of MORF-057, an oral small molecule inhibitor of the α4β7 integrin, in adults with moderate to severe ulcerative colitis (UC). MORF-057 achieved the primary endpoint, demonstrating a statistically significant reduction in the Robarts Histopathology Index (RHI) score of 6.4 points (p=0.002) from baseline to week 12. MORF-057 was generally well tolerated at the dose of 100 mg BID (twice daily) with no serious adverse events (SAEs) and no safety signal.